IPIX Projected Dividend Yield

Cl A Com/Innovation Pharmaceuticals Inc ( OTCBB : IPIX )

Innovation Pharmaceuticals is a clinical stage pharmaceutical company developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. Co.'s main drug candidate Brilacidin is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. Co.'s efforts are primarily focused on advancement of Brilacidin in Oral Mucositis and in infectious diseases. Brilacidin is being developed for the treatment of Oral Mucositis, Inflammatory Bowel Disease and Acute Bacterial Skin and Skin Structure Infection.

20 YEAR PERFORMANCE RESULTS